Modified clostridial toxins with altered targeting...

Details Modified clostridial toxins with altered targeting... Modified clostridial toxins with altered targeting...

2006-03-14

2011-11-08

Swartz, Rodney P. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S184100, C424S192100, C424S234100, C424S236100, C536S023100, C536S023700

Reexamination Certificate

active

08052979

ABSTRACT:
The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.

REFERENCES:
patent: 5668255 (1997-09-01), Murphy
patent: 5939070 (1999-08-01), Johnson et al.
patent: 6461617 (2002-10-01), Shone et al.
patent: 6500436 (2002-12-01), Donovan
patent: 6632440 (2003-10-01), Quinn et al.
patent: 6641820 (2003-11-01), Donovan
patent: 6843998 (2005-01-01), Steward et al.
patent: 6962703 (2005-11-01), Foster et al.
patent: 7052702 (2006-05-01), Duggan et al.
patent: 7056729 (2006-06-01), Donovan
patent: 7132259 (2006-11-01), Dolly et al.
patent: 7138127 (2006-11-01), Donovan
patent: 7192596 (2007-03-01), Shone et al.
patent: 7244436 (2007-07-01), Donovan
patent: 7244437 (2007-07-01), Donovan
patent: 7262291 (2007-08-01), Donovan
patent: 2003/0180289 (2003-09-01), Foster
patent: 2004/0071736 (2004-04-01), Quinn et al.
patent: 2006/0099672 (2006-05-01), Dolly
patent: 2006/0110410 (2006-05-01), Shone et al.
patent: 2006/0121056 (2006-06-01), Chaddock
patent: 2008/0032931 (2008-02-01), Steward et al.
patent: 2008/0081355 (2008-04-01), Dolly et al.
patent: 2008/0161226 (2008-07-01), Steward et al.
patent: 2008/0161543 (2008-07-01), Steward et al.
patent: WO 94/21300 (1994-09-01), None
patent: WO 00/57897 (2000-10-01), None
patent: WO 01/14570 (2001-03-01), None
patent: WO 2004/024909 (2004-03-01), None
patent: WO 2005/023309 (2005-03-01), None
patent: WO 2006/009831 (2006-03-01), None
patent: WO 2006/059093 (2006-06-01), None
patent: WO 2006/059105 (2006-06-01), None
patent: WO2006/059113 (2006-06-01), None
Herreros et al, “C-Terminal Half of Tetanus Toxin Fragment C is Sufficient for Neuronal Binding and Interaction with a Putative Protein Receptor”, Biochemical Journal, vol. 347, No. Part 1, pp. 199-204, Apr. 1, 2001.
Rummel et al, “The Hcc-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interation”, Molecular Microbiology, pp. 631-643, Dec. 15, 2003.
Halpern et al, “Characterization of the receptor-binding domain of tetanus toxin”, Journal of Biological Chemistry, pp. 11188-11192, May 25, 1993.
U.S. Appl. No. 11/466,244, filed Aug. 22, 2006, Donovan.
U.S. Appl. No. 11/610,440, filed Dec. 13, 2006, Dolly et al.
U.S. Appl. No. 11/765,863, filed Jun. 20, 2007, Donovan.
U.S. Appl. No. 11/765,878, filed Jun. 20, 2007, Donovan.
U.S. Appl. No. 11/781,359, filed Jul. 23, 2007, Dolly et al.
U.S. Appl. No. 11/782,112, filed Jul. 24, 2007, Dolly et al.
U.S. Appl. No. 11/829,475, filed Jul. 27, 2007, Steward et al.
U.S. Appl. No. 11/832,108, filed Aug. 1, 2007, Steward et al.
U.S. Appl. No. 11/832,173, filed Aug. 1, 2007, Steward et al.
U.S. Appl. No. 11/833,142, filed Aug. 2, 2007, Steward et al.
U.S. Appl. No. 11/833,720, filed Aug. 3, 2007, Steward et al.
U.S. Appl. No. 11/834,068, filed Aug. 6, 2007, Steward et al.
U.S. Appl. No. 11/844,780, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,850, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,885, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,929, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,919, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,899, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,517, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,546, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/845,167, Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,252, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,284, Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,320, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,345, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,466, filed Aug. 27, 2007, Steward et al.
Chaddock, J. A., et al., A conjugate composed of nerve growth factor coupled to a non-toxic derivative ofClostridium botulinumneurotoxin type A can inhibit neurotransmitter release in vitro, 18(2) Growth Factors 147-155 (2000).
Gozes, I., Furman, S., Potential clinical applications of vasoactive intestinal peptide: a selected update, 18(4) Best Prac. Res. Clinical Endocrin. Metab. 623-640 (2004).
Duggan, M. J., et al., Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of aClostridium botulinumtoxin A endopeptidase fragment andErythrina cristagallilectin, 277(38) J. Biol. Chem. 34846-34852 (2002).

Affiliated with

Also associated with

Rating

Modified clostridial toxins with altered targeting... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified clostridial toxins with altered targeting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified clostridial toxins with altered targeting... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4304140